TRY IT!

GET YOUR FREE DEMO KIT

$10 COPAY OFFER

References

Boudriau S, Harvey C, Massicotte J, et al. Randomized Comparative bioavailability of a novel three-dimensional printed fast-melt formulation of levetiracetam following the administration of a single 1000-mg dose to healthy human volunteers under fasting and fed conditions. Drugs R D. 2016;16(2):229–238.

Channer K, Virjee JP. The effect of size and shape of tablets on their esophageal transit. J Clin Pharmacol. 1986;26:141–146.

Data on file. Aprecia Pharmaceuticals, LLC.

40% of American adults report experiencing difficulty swallowing pills [press release]. New York, NY: PR Newswire; January 15, 2004.

Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient’s perspective.

Ther Clin Risk Manag. 2008;4(1):269–286.

Liu F, Ranmal S, Batchelor HK, et al. Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations. Drugs. 2014;74(16):1871–1889.

Lyseng-Williamson KA. Spotlight on levetiracetam in epilepsy. CNS Drugs. 2011;25(10):901–905.

National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. 2015;137:1–117.

OTC Company News. Hermes highlights need for better formats. http://www.hermes-pharma.com/fileadmin/data/download/
Hermes_highlights_need_for_better_formats_OTCBulletin_250714.pdf.
Published July 2014. Accessed July 10, 2016.

Robbins J, Langmore S, Hind JA, Erlichman M. Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001. J Rehabil Res Dev. 2002;39(4):543–548.

SPRITAM Medication Guide. Aprecia Pharmaceuticals, LLC.

SPRITAM Full Prescribing Information. Aprecia Pharmaceuticals, LLC.

Tablets and capsules that stick in the oesophagus. Drug Ther Bull. 1981;19(9):33–34.

US Food and Drug Administration. Size, shape, and other physical attributes of generic tablets and capsules. Washington, DC: US Department of Health and Human Services; 2015.